首页> 美国卫生研究院文献>New Microbes and New Infections >Diagnostic approaches and potential therapeutic options for coronavirus disease 2019
【2h】

Diagnostic approaches and potential therapeutic options for coronavirus disease 2019

机译:2019年冠状病毒疾病的诊断方法及潜在治疗选择

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city of China in late December 2019 and identified as a novel coronavirus. Due to its contagious nature, the virus spreads rapidly and causes coronavirus disease 2019 (COVID-19). The global tally of COVID-19 was 28 million in early September 2020. The fears and stress associated with SARS-CoV-2 has demolished the socio-economic status worldwide. Researchers are trying to identify treatments, especially antiviral drugs and/or vaccines, that could potentially control the viral spread and manage the ongoing unprecedented global crisis. To date, more than 300 clinical trials have been conducted on various antiviral drugs, and immunomodulators are being evaluated at various stages of COVID-19. This review aims to collect and summarize a list of drugs used to treat COVID-19, including dexamethasone, chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, remdesivir, tociluzimab, nitazoxanide and ivermectin. However, some of these drugs are not effective and their use has been suspended by WHO.
机译:2019年12月下旬,中国武汉市出现了严重的急性呼吸综合征冠状病毒2(SARS-COV-2),并被确定为一个新的冠状病毒。由于其传染性,病毒迅速传播并导致2019年冠状病毒疾病(Covid-19)。 Covid-19的全球计数于2020年9月初为2800万。与SARS-COV-2相关的恐惧和压力拆除了全世界的社会经济地位。研究人员正在努力识别治疗,特别是抗病毒药物和/或疫苗,这可能会控制病毒蔓延和管理正在进行的前所未有的全球危机。迄今为止,已经在各种抗病毒药物中进行了超过300种临床试验,并且在Covid-19的各个阶段进行免疫调节剂。该审查旨在收集和总结用于治疗Covid-19的药物清单,包括地塞米松,氯喹,羟氯喹,Lopinavir / Ritonavir,FaviPiravir,Remdesivir,Tocoluzimab,Nitazoxanide和Ivermectin。然而,其中一些药物无效,其使用已被世卫组织暂停。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号